Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.

Recent findings suggest that relationship partners who discuss concerns and agree on limits about substance use may be better able to regulate use.